This is a modest procedural win that keeps Regeneron's scienter defense alive but does not resolve the core FCA liability question. Monitor the meet-and-confer deadline of September 7, 2026, and any subsequent rulings on the scope of the narrowed discovery. The FCA case remains a material overhang, a future adverse ruling on summary judgment or at trial would be significantly more impactful.
Drug in focus
REGN drug pipeline →EYLEA HD
● Neutral Named in this court ruling- Impact
- Phase
- Approved
- Time to market
- Already approved and on the market (since August 2023)
- Next catalyst
- None dated
What to watchEYLEA HD is a mature commercial asset, watch quarterly sales trends as a pulse check on how well Regeneron is defending share against Roche's Vabysmo and upcoming biosimilars (Samsung Bioepis Opuviz eligible Jan 2027). The real binary catalyst for REGN in the next 12 months is garetosmab's PDUFA in August 2026 for FOP. EYLEA HD's contribution is a gradual commercial story, not a binary event.
- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● Libtayo 4/10 Approved
- 11 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 25 $833.56entry
- T+1 · 3mo ago −2.25%α −2.27% · $814.79
- T+5 · 3mo ago −1.17%α −0.63% · $823.82
- T+20 · 8w ago −3.81%α −4.06% · $801.82
- T+58 · todayOpen
- T+60 · tomorrow Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A federal magistrate judge partially granted and partially denied motions to quash subpoenas served by Regeneron on non-party drug manufacturers (EyePoint, Ocular Therapeutix, Novartis) in a False Claims Act qui tam case. The court ruled that industry practice evidence is relevant to Regeneron's scienter defense but not to falsity or materiality, and limited Regeneron to seeking narrow discovery from no more than ten manufacturers on whether they included credit card fee reimbursements in ASP calculations for buy-and-bill drugs from 2020-2024. This is a modest procedural win for Regeneron, it preserves a potential defense pathway but does not resolve the underlying FCA exposure, which remains a material overhang on the stock.
Court Ruling Details
Key Facts
- Regeneron is defending a False Claims Act qui tam action alleging it fraudulently inflated Eylea's ASP by failing to deduct credit card fee reimbursements to distributors as price concessions.
- The court ruled that industry practice evidence is relevant to the scienter (knowledge) element of the FCA claim, allowing Regeneron to pursue limited discovery on this issue.
- Regeneron may seek information from no more than ten non-party manufacturers on whether they included credit card fee reimbursements in their ASP calculations for buy-and-bill drugs between January 1, 2020 and March 28, 2024.
- The court denied the motions to quash in part, finding that the non-party manufacturers' general claims of burden did not excuse production entirely, though it ordered cost-sharing.
- The ruling does not address the merits of the FCA claim, it is a discovery ruling that narrows but does not eliminate Regeneron's ability to build a scienter defense.
Financial Impact
Not quantifiable from this ruling, no damages or settlement amounts are stated. The underlying FCA case could involve material exposure if Regeneron is found liable, but this ruling only concerns discovery scope.
Risk Factors
- The court explicitly ruled that industry practice evidence is irrelevant to falsity and materiality, limiting the scope of Regeneron's defense.
- The underlying FCA case remains unresolved, this discovery ruling does not reduce the probability of a future adverse judgment or settlement.
- Regeneron is limited to no more than ten manufacturers and a narrow time window (2020-2024), which may not yield exculpatory evidence.
- The government's FCA claim could proceed to summary judgment or trial regardless of what the discovery shows about industry practice.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2e4a6e1337-REGN |
Track record
53 reports on REGN
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers